Item 7.01 Regulation FD Disclosure. CareDx, Inc. (“CareDx” or the “Company”) is furnishing a press release, attached as Exhibit 99.1 to this Current Report on Form 8-K (the “Press Release”), which the Company intends to post on the Company’s website. The Press Release is current as of June 3, 2025, and the Company disclaims any obligation to update this material in the future.…
Filed Jun 3, 2025Accepted Jun 3, 2025, 4:30 PM EDTCIK 1217234Accession 0001193125-25-134150
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company’s integrated solutions include non invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics based information for transplant patients. For more information, please visit www.caredx.com.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
CareDx, Inc. (“CareDx” or the “Company”) is furnishing a press release, attached as Exhibit 99.1 to this Current Report on Form 8-K (the “Press Release”), which the Company intends to post on the Company’s website. The Press Release is current as of June 3, 2025, and the Company disclaims any obligation to update this material in the future.
The information in this Item 7.01, including the Press Release attached hereto as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ( the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On May 30, 2025, the Board of Directors (the “Board”) of CareDx authorized a common stock repurchase program of up to $50 million in shares for up to 24 months from June 5, 2025. Under the repurchase program, CareDx may purchase shares of common stock on a discretionary basis from time to time through open market repurchases, privately negotiated transactions or other means, including through Rule 10b5-1 trading plans or through the use of other techniques. The timing and number of shares repurchased, and the price of any repurchases, will depend on a variety of factors, including stock price, trading volume, and general business and market conditions. The repurchase program does not obligate CareDx to acquire a specified number of shares and may be modified, suspended, or discontinued at any time at CareDx’s discretion. Repurchases under this program will be funded from CareDx’s existing cash and cash equivalents or future cash flow.
The Board’s authorization for this program follows the completion of a prior $50 million stock repurchase program that was authorized by the Board in February 2025. Under that program, CareDx repurchased 3,031,533 shares.
Filed exhibits (1)
EX-99.1 (by filename) d936250dex991.htm
EX-99.1
2
d936250dex991.htm
EX-99.1
EX-99.1
Exhibit 99.1
CareDx Announces Repurchase of 5% of Outstanding Shares
Board of Directors Authorizes New $50 Million Share Repurchase Program
BRISBANE, Calif. - CareDx, Inc. (Nasdaq: CDNA), - The Transplant Company™ - a
leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has completed the
repurchase of $50 million of its common stock representing approximately 5% of outstanding shares.
The share repurchase follows the completion of
the company’s seventh consecutive quarter of testing services volume growth and a first-quarter total revenue of $84.7 million, representing 18% year-over-year growth. CareDx ended the first quarter with $231 million in cash, cash
equivalents, marketable securities, and no debt.
“The investments we have made in our commercial organization and operational infrastructure are
translating into growth. We saw a clear opportunity to return value to our shareholders at our current price without disrupting the ongoing development of our innovat…
